260 related articles for article (PubMed ID: 27304188)
41. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
Song HN; Jung KS; Yoo KH; Cho J; Lee JY; Lim SH; Kim HS; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Park W; Ahn MJ
J Thorac Oncol; 2016 Apr; 11(4):e45-7. PubMed ID: 26749488
[TBL] [Abstract][Full Text] [Related]
42. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
43. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
44. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
45. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
Hidaka N; Iwama E; Kubo N; Harada T; Miyawaki K; Tanaka K; Okamoto I; Baba E; Akashi K; Sasaki H; Nakanishi Y
Lung Cancer; 2017 Jun; 108():75-82. PubMed ID: 28625653
[TBL] [Abstract][Full Text] [Related]
46. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
Park S; Shim JH; Lee B; Cho I; Park WY; Kim Y; Lee SH; Choi Y; Han J; Ahn JS; Ahn MJ; Park K; Sun JM
Lung Cancer; 2019 Aug; 134():7-15. PubMed ID: 31319998
[TBL] [Abstract][Full Text] [Related]
47. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
[TBL] [Abstract][Full Text] [Related]
48. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
49. Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
Bonanno L; Calabrese F; Nardo G; Calistri D; Tebaldi M; Tedaldi G; Polo V; Vuljan S; Favaretto A; Conte P; Amadori A; Rea F; Indraccolo S
Lung Cancer; 2016 Jun; 96():52-5. PubMed ID: 27133750
[TBL] [Abstract][Full Text] [Related]
50. Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
Xu S; Liu X; Liu R; Shi T; Li X; Zhong D; Wang Y; Chen G; Chen J
Thorac Cancer; 2017 Nov; 8(6):693-697. PubMed ID: 28786540
[TBL] [Abstract][Full Text] [Related]
51. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
Serna-Blasco R; Sánchez-Herrero E; Sanz-Moreno S; Rodriguez-Festa A; García-Veros E; Casarrubios M; Sierra-Rodero B; Laza-Briviesca R; Cruz-Bermúdez A; Mielgo-Rubio X; Sánchez-Hernández A; Uribelarrea EA; Calvo V; Romero A; Provencio M
ESMO Open; 2021 Oct; 6(5):100279. PubMed ID: 34607284
[TBL] [Abstract][Full Text] [Related]
52. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
53. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
[TBL] [Abstract][Full Text] [Related]
54. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
[TBL] [Abstract][Full Text] [Related]
55. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T
Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932
[TBL] [Abstract][Full Text] [Related]
56. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
57. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
58. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Lee Y; Choi YR; Kim KY; Shin DH
Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
[TBL] [Abstract][Full Text] [Related]
59. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
60. Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.
Song Z; Yu X; Zhang Y
Cancer Med; 2016 Oct; 5(10):2694-2700. PubMed ID: 27554588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]